{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:18:01Z","timestamp":1787642281913,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ekir.2021.10.017","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T23:12:49Z","timestamp":1635549169000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte \u03b23 Integrin"],"prefix":"10.1016","volume":"7","author":[{"given":"Michelle A.","family":"Hladunewich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev M.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah I.","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2021.10.017_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2021.10.017_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/14.suppl_3.68","article-title":"Clinical picture and outcome of primary focal segmental glomerulosclerosis","volume":"14","author":"Korbet","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.10.017_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib4","first-page":"568","article-title":"Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis","volume":"58","author":"Velosa","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2021.10.017_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.transproceed.2008.03.076","article-title":"Renal transplantation in primary focal segmental glomerulosclerosis using a tolerance induction protocol","volume":"40","author":"Suthar","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2021.10.017_bib7","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/j.1600-6143.2005.01112.x","article-title":"Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients","volume":"5","author":"Gohh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2021.10.017_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/153537020422900111","article-title":"The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects","volume":"229","author":"Sharma","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ekir.2021.10.017_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/TP.0b013e318250234a","article-title":"Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis","volume":"93","author":"Chang","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2021.10.017_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2012.10.011","article-title":"Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child","volume":"61","author":"Kemper","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.10.017_bib12","first-page":"324","article-title":"Fetal renal echogenicity associated with maternal focal segmental glomerulosclerosis: the effect of transplacental transmission of permeability factor suPAR","volume":"7","author":"Shuster","year":"2018","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib13","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation","volume":"366","author":"Gallon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib15","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI124793","article-title":"uPAR isoform 2 forms a dimer and induces severe kidney disease in mice","volume":"129","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2021.10.017_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.10.017_bib17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/ndt\/15.9.1348","article-title":"Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis","volume":"15","author":"Alexopoulos","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.10.017_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","article-title":"Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment","volume":"25","author":"Rydel","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.10.017_bib19","doi-asserted-by":"crossref","first-page":"c75","DOI":"10.1159\/000093993","article-title":"Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study","volume":"104","author":"Goumenos","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2021.10.017_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11255-008-9393-0","article-title":"Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab","volume":"40","author":"Suri","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","article-title":"Rituximab for refractory focal segmental glomerulosclerosis","volume":"23","author":"Nakayama","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-6143.2007.02021.x","article-title":"Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis","volume":"8","author":"Yabu","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2021.10.017_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5414\/CNP67250","article-title":"Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports","volume":"67","author":"Kamar","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1432-2277.2007.00562.x","article-title":"Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis","volume":"20","author":"Meyer","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2021.10.017_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1432-2277.2007.00477.x","article-title":"Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis","volume":"20","author":"Gossmann","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2021.10.017_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1432-2277.2006.00395.x","article-title":"Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab","volume":"20","author":"Hristea","year":"2007","journal-title":"Transpl Int"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2021.10.017_bib28","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.10.017_bib29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","article-title":"Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review","volume":"197","author":"Jellouli","year":"2018","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ekir.2021.10.017_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12882-018-1177-x","article-title":"Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab","volume":"19","author":"Alachkar","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.10.017_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ki.2014.346","article-title":"A\u00a0reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease","volume":"87","author":"Spinale","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.10.017_bib36","first-page":"5679518","article-title":"Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) levels in FSGS: a meta-analysis","volume":"2019","author":"Lee","year":"2019","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.ekir.2021.10.017_bib37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm.4362","article-title":"A\u00a0tripartite complex of suPAR, APOL1 risk variants and \u03b1v\u03b23 integrin on podocytes mediates chronic kidney disease","volume":"23","author":"Hayek","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib38","doi-asserted-by":"crossref","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","article-title":"A\u00a0circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation","volume":"6","author":"Delville","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2021.10.017_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.atherosclerosis.2018.03.030","article-title":"Effect of simvastatin and ezetimibe on suPAR levels and outcomes","volume":"272","author":"Hodges","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2021.10.017_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/gerona\/glaa178","article-title":"Association between elevated suPAR, a new biomarker of inflammation, and accelerated aging","volume":"76","author":"Rasmussen","year":"2021","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ekir.2021.10.017_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ekir.2017.02.001","article-title":"Cardiovascular disease biomarkers and suPAR in predicting decline in renal function: a prospective cohort study","volume":"2","author":"Hayek","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2021.10.017_bib42","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1038\/s41598-019-50405-8","article-title":"Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method","volume":"9","author":"Winnicki","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2021.10.017_bib43","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1\u2013positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492101500X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492101500X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:38:15Z","timestamp":1762832295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492101500X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S246802492101500X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2021.10.017","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte \u03b23 Integrin","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}